Teva Announces Its Launch of the First Generic PERFOROMIST®, Formoterol Fumarate Inhalation Solution, 20 Mcg/2 ML, Used to Treat Chronic Obstructive Pulmonary Disease (COPD), in the United States

Teva Pharmaceuticals, Ltd. announced its US launch of the first generic version of twice daily PERFOROMIST^®,formoterol fumarate inhalation solution, 20 mcg/2 ML, indicated to treat bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.